Trade Chromadex Corp - CDXC CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0280 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Chromadex Corp ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 1.426 |
| Open* | 1.436 |
| 1-Year Change* | 12.19% |
| Day's Range* | 1.366 - 1.436 |
| 52 wk Range | 1.15-2.24 |
| Average Volume (10 days) | 70.73K |
| Average Volume (3 months) | 1.83M |
| Market Cap | 114.80M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 75.03M |
| Revenue | 80.94M |
| EPS | -0.09 |
| Dividend (Yield %) | N/A |
| Beta | 1.79 |
| Next Earnings Date | Oct 31, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Oct 4, 2023 | 1.3760 | -0.0400 | -2.82% | 1.4160 | 1.4560 | 1.3460 |
| Oct 3, 2023 | 1.4260 | -0.0200 | -1.38% | 1.4460 | 1.4460 | 1.4060 |
| Oct 2, 2023 | 1.4460 | 0.0300 | 2.12% | 1.4160 | 1.4660 | 1.4160 |
| Sep 29, 2023 | 1.4260 | 0.0400 | 2.89% | 1.3860 | 1.4560 | 1.3760 |
| Sep 28, 2023 | 1.3960 | 0.0000 | 0.00% | 1.3960 | 1.4460 | 1.3760 |
| Sep 27, 2023 | 1.4260 | 0.0000 | 0.00% | 1.4260 | 1.4360 | 1.3760 |
| Sep 26, 2023 | 1.4060 | 0.0600 | 4.46% | 1.3460 | 1.4160 | 1.3260 |
| Sep 25, 2023 | 1.3560 | 0.0000 | 0.00% | 1.3560 | 1.3860 | 1.3560 |
| Sep 22, 2023 | 1.3660 | 0.0000 | 0.00% | 1.3660 | 1.3860 | 1.3560 |
| Sep 21, 2023 | 1.3760 | -0.0100 | -0.72% | 1.3860 | 1.3960 | 1.3560 |
| Sep 20, 2023 | 1.3760 | -0.0100 | -0.72% | 1.3860 | 1.4060 | 1.3660 |
| Sep 19, 2023 | 1.4160 | 0.0400 | 2.91% | 1.3760 | 1.4360 | 1.3760 |
| Sep 18, 2023 | 1.3960 | -0.0600 | -4.12% | 1.4560 | 1.4660 | 1.3860 |
| Sep 15, 2023 | 1.4660 | 0.0500 | 3.53% | 1.4160 | 1.4960 | 1.4160 |
| Sep 14, 2023 | 1.4660 | 0.0500 | 3.53% | 1.4160 | 1.4760 | 1.4160 |
| Sep 13, 2023 | 1.3960 | -0.0100 | -0.71% | 1.4060 | 1.4260 | 1.3760 |
| Sep 12, 2023 | 1.4360 | -0.0500 | -3.36% | 1.4860 | 1.4960 | 1.4160 |
| Sep 11, 2023 | 1.5160 | 0.0300 | 2.02% | 1.4860 | 1.5160 | 1.4860 |
| Sep 8, 2023 | 1.5160 | 0.0000 | 0.00% | 1.5160 | 1.5260 | 1.4860 |
| Sep 7, 2023 | 1.5160 | -0.0100 | -0.66% | 1.5260 | 1.5460 | 1.5060 |
Chromadex Corp Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, October 31, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 Chromadex Corp Earnings Release Q3 2023 Chromadex Corp Earnings ReleaseForecast -Previous - |
| Wednesday, March 6, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Chromadex Corp Earnings Release Q4 2023 Chromadex Corp Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 72.05 | 67.449 | 59.257 | 46.291 | 31.557 |
| Revenue | 72.05 | 67.449 | 59.257 | 46.291 | 31.557 |
| Cost of Revenue, Total | 29.253 | 25.959 | 23.983 | 20.522 | 15.502 |
| Gross Profit | 42.797 | 41.49 | 35.274 | 25.769 | 16.055 |
| Total Operating Expense | 90.678 | 94.522 | 79.111 | 77.591 | 64.729 |
| Selling/General/Admin. Expenses, Total | 56.599 | 64.731 | 51.396 | 52.524 | 43.674 |
| Research & Development | 4.826 | 3.832 | 3.732 | 4.42 | 5.478 |
| Unusual Expense (Income) | |||||
| Other Operating Expenses, Total | 0 | 0.125 | 0.075 | ||
| Operating Income | -18.628 | -27.073 | -19.854 | -31.3 | -33.172 |
| Interest Income (Expense), Net Non-Operating | 0.003 | -0.055 | -0.071 | -0.847 | -0.079 |
| Net Income Before Taxes | -16.54 | -27.128 | -19.925 | -32.147 | -33.316 |
| Net Income After Taxes | -16.54 | -27.128 | -19.925 | -32.147 | -33.316 |
| Net Income Before Extra. Items | -16.54 | -27.128 | -19.925 | -32.147 | -33.316 |
| Total Extraordinary Items | 0 | ||||
| Net Income | -16.54 | -27.128 | -19.925 | -32.147 | -33.316 |
| Income Available to Common Excl. Extra. Items | -16.54 | -27.128 | -19.925 | -32.147 | -33.316 |
| Income Available to Common Incl. Extra. Items | -16.54 | -27.128 | -19.925 | -32.147 | -33.316 |
| Diluted Net Income | -16.54 | -27.128 | -19.925 | -32.147 | -33.316 |
| Diluted Weighted Average Shares | 69.729 | 67.185 | 61.067 | 57.056 | 55.006 |
| Diluted EPS Excluding Extraordinary Items | -0.2372 | -0.40378 | -0.32628 | -0.56343 | -0.60568 |
| Diluted Normalized EPS | -0.2372 | -0.40378 | -0.32628 | -0.56343 | -0.60568 |
| Other, Net | 2.085 | 0 | -0.065 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 20.323 | 22.556 | 20.996 | 17.063 | 16.732 |
| Revenue | 20.323 | 22.556 | 20.996 | 17.063 | 16.732 |
| Cost of Revenue, Total | 7.967 | 9.038 | 8.98 | 6.856 | 6.69 |
| Gross Profit | 12.356 | 13.518 | 12.016 | 10.207 | 10.042 |
| Total Operating Expense | 22.639 | 24.524 | 22.44 | 20.128 | 23.119 |
| Selling/General/Admin. Expenses, Total | 13.307 | 14.293 | 12.181 | 12.048 | 15.184 |
| Research & Development | 1.365 | 1.193 | 1.279 | 1.224 | 1.245 |
| Operating Income | -2.316 | -1.968 | -1.444 | -3.065 | -6.387 |
| Interest Income (Expense), Net Non-Operating | 0.125 | 0.066 | 0.026 | -0.005 | -0.01 |
| Net Income Before Taxes | -2.191 | -1.902 | -1.418 | -0.985 | -6.397 |
| Net Income After Taxes | -2.191 | -1.902 | -1.418 | -0.985 | -6.397 |
| Net Income Before Extra. Items | -2.191 | -1.902 | -1.418 | -0.985 | -6.397 |
| Net Income | -2.191 | -1.902 | -1.418 | -0.985 | -6.397 |
| Income Available to Common Excl. Extra. Items | -2.191 | -1.902 | -1.418 | -0.985 | -6.397 |
| Income Available to Common Incl. Extra. Items | -2.191 | -1.902 | -1.418 | -0.985 | -6.397 |
| Diluted Net Income | -2.191 | -1.902 | -1.418 | -0.985 | -6.397 |
| Diluted Weighted Average Shares | 74.967 | 74.796 | 73.923 | 68.345 | 68.336 |
| Diluted EPS Excluding Extraordinary Items | -0.02923 | -0.02543 | -0.01918 | -0.01441 | -0.09361 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.02923 | -0.02543 | -0.01918 | -0.01441 | -0.09361 |
| Other, Net | 0 | 2.085 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 46.567 | 48.905 | 32.219 | 33.518 | 36.534 |
| Cash and Short Term Investments | 20.241 | 28.219 | 16.697 | 18.812 | 22.616 |
| Cash | 20.241 | 28.219 | 16.697 | 18.812 | 22.616 |
| Total Receivables, Net | 8.482 | 5.226 | 2.694 | 2.175 | 5.092 |
| Accounts Receivable - Trade, Net | 5.382 | 3.126 | 1.794 | 1.375 | 4.415 |
| Total Inventory | 14.677 | 13.601 | 11.683 | 11.535 | 8.249 |
| Prepaid Expenses | 2.967 | 1.859 | 1.145 | 0.996 | 0.577 |
| Total Assets | 54.057 | 57.84 | 38.358 | 40.247 | 42.232 |
| Property/Plant/Equipment, Total - Net | 6.322 | 7.355 | 4.432 | 4.656 | 3.585 |
| Property/Plant/Equipment, Total - Gross | 11.899 | 8.086 | 7.446 | 5.636 | |
| Accumulated Depreciation, Total | -4.544 | -3.654 | -2.79 | -2.051 | |
| Intangibles, Net | 0.671 | 0.857 | 1.082 | 1.311 | 1.547 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 0.497 | 0.723 | 0.625 | 0.762 | 0.566 |
| Total Current Liabilities | 17.869 | 17.613 | 16.476 | 15.063 | 14.44 |
| Accounts Payable | 9.679 | 10.423 | 9.445 | 9.626 | 9.548 |
| Accrued Expenses | 8.017 | 7.009 | 6.722 | 5.01 | 4.313 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.016 | 0.02 | 0.031 | 0.258 | 0.173 |
| Other Current Liabilities, Total | 0.157 | 0.161 | 0.278 | 0.169 | 0.406 |
| Total Liabilities | 25.385 | 26.113 | 21.934 | 19.802 | 15.054 |
| Total Long Term Debt | 0.022 | 0 | 0.02 | 0.018 | 0.137 |
| Long Term Debt | |||||
| Capital Lease Obligations | 0.022 | 0 | 0.02 | 0.018 | 0.137 |
| Other Liabilities, Total | 7.494 | 8.5 | 5.438 | 4.721 | 0.477 |
| Total Equity | 28.672 | 31.727 | 16.424 | 20.445 | 27.178 |
| Common Stock | 0.074 | 0.068 | 0.062 | 0.06 | 0.055 |
| Additional Paid-In Capital | 214.094 | 200.614 | 158.19 | 142.285 | 116.876 |
| Retained Earnings (Accumulated Deficit) | -185.493 | -168.953 | -141.825 | -121.9 | -89.753 |
| Total Liabilities & Shareholders’ Equity | 54.057 | 57.84 | 38.358 | 40.247 | 42.232 |
| Total Common Shares Outstanding | 74.567 | 68.126 | 61.881 | 59.562 | 55.089 |
| Other Current Assets, Total | 0.2 | ||||
| Note Receivable - Long Term | 0 | ||||
| Other Equity, Total | -0.003 | -0.002 | -0.003 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 46.565 | 46.567 | 37.901 | 38.508 | 44.523 |
| Cash and Short Term Investments | 22.989 | 20.241 | 13.062 | 16.872 | 20.793 |
| Cash | 22.989 | 20.241 | 13.062 | 16.872 | 20.793 |
| Total Receivables, Net | 9.221 | 8.482 | 4.744 | 4.228 | 6.31 |
| Accounts Receivable - Trade, Net | 12.721 | 5.382 | 2.344 | 2.928 | 8.61 |
| Total Inventory | 11.908 | 14.677 | 15.636 | 15.753 | 15.307 |
| Prepaid Expenses | 2.295 | 2.967 | 4.259 | 1.455 | 1.913 |
| Total Assets | 53.768 | 54.057 | 45.665 | 46.613 | 52.93 |
| Property/Plant/Equipment, Total - Net | 6.041 | 6.322 | 6.505 | 6.783 | 6.993 |
| Intangibles, Net | 0.63 | 0.671 | 0.714 | 0.758 | 0.808 |
| Other Long Term Assets, Total | 0.532 | 0.497 | 0.545 | 0.564 | 0.606 |
| Total Current Liabilities | 18.423 | 17.869 | 16.727 | 17.725 | 18.694 |
| Accounts Payable | 8.951 | 9.679 | 9.119 | 10.197 | 9.78 |
| Accrued Expenses | 9.307 | 8.017 | 7.44 | 7.342 | 8.756 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.017 | 0.016 | 0.01 | 0.013 | 0.017 |
| Other Current Liabilities, Total | 0.148 | 0.157 | 0.158 | 0.173 | 0.141 |
| Total Liabilities | 25.751 | 25.385 | 24.642 | 25.835 | 27.053 |
| Total Long Term Debt | 0.02 | 0.022 | 0 | 0 | 0 |
| Capital Lease Obligations | 0.02 | 0.022 | |||
| Other Liabilities, Total | 7.308 | 7.494 | 7.915 | 8.11 | 8.359 |
| Total Equity | 28.017 | 28.672 | 21.023 | 20.778 | 25.877 |
| Common Stock | 0.074 | 0.074 | 0.068 | 0.068 | 0.068 |
| Additional Paid-In Capital | 215.367 | 214.094 | 205.027 | 203.798 | 202.502 |
| Retained Earnings (Accumulated Deficit) | -187.424 | -185.493 | -184.075 | -183.09 | -176.693 |
| Other Equity, Total | 0 | -0.003 | 0.003 | 0.002 | 0 |
| Total Liabilities & Shareholders’ Equity | 53.768 | 54.057 | 45.665 | 46.613 | 52.93 |
| Total Common Shares Outstanding | 74.666 | 74.567 | 68.169 | 68.155 | 68.149 |
| Other Current Assets, Total | 0.152 | 0.2 | 0.2 | 0.2 | 0.2 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.54 | -27.128 | -19.925 | -32.147 | -33.316 |
| Cash From Operating Activities | -15.098 | -24.163 | -10.6 | -20.439 | -20.908 |
| Cash From Operating Activities | 0.869 | 0.89 | 0.871 | 0.762 | 0.607 |
| Amortization | 0.186 | 0.225 | 0.243 | 0.246 | 0.235 |
| Non-Cash Items | 6.705 | 6.86 | 5.252 | 10.902 | 6.375 |
| Cash Interest Paid | 0.001 | 0.001 | 0.013 | 0.033 | 0.041 |
| Changes in Working Capital | -6.318 | -5.01 | 2.959 | -0.202 | 5.191 |
| Cash From Investing Activities | -0.334 | -0.409 | -0.165 | -0.249 | -1.775 |
| Capital Expenditures | -0.334 | -0.409 | -0.142 | -0.753 | -1.452 |
| Other Investing Cash Flow Items, Total | 0 | -0.023 | 0.504 | -0.323 | |
| Cash From Financing Activities | 7.654 | 36.094 | 8.65 | 16.884 | -0.09 |
| Financing Cash Flow Items | -0.077 | -0.11 | -0.049 | -0.678 | -0.019 |
| Issuance (Retirement) of Stock, Net | 7.747 | 36.235 | 8.971 | 7.838 | 0.125 |
| Issuance (Retirement) of Debt, Net | -0.016 | -0.031 | -0.272 | 9.724 | -0.196 |
| Net Change in Cash | -7.778 | 11.522 | -2.115 | -3.804 | -22.773 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -1.902 | -16.54 | -15.122 | -14.137 | -7.74 |
| Cash From Operating Activities | 2.792 | -15.098 | -14.77 | -11.03 | -7.198 |
| Cash From Operating Activities | 0.228 | 0.869 | 0.648 | 0.413 | 0.201 |
| Amortization | 0.041 | 0.186 | 0.143 | 0.099 | 0.049 |
| Non-Cash Items | 1.781 | 6.705 | 5.14 | 3.713 | 2.215 |
| Cash Interest Paid | 0.001 | 0 | 0 | 0 | |
| Changes in Working Capital | 2.644 | -6.318 | -5.579 | -1.118 | -1.923 |
| Cash From Investing Activities | -0.091 | -0.334 | -0.162 | -0.11 | -0.025 |
| Capital Expenditures | -0.091 | -0.334 | -0.162 | -0.11 | -0.025 |
| Other Investing Cash Flow Items, Total | |||||
| Cash From Financing Activities | -0.001 | 7.654 | -0.025 | -0.007 | -0.003 |
| Financing Cash Flow Items | -0.077 | -0.015 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 7.747 | 0 | 0 | 0 | |
| Issuance (Retirement) of Debt, Net | -0.001 | -0.016 | -0.01 | -0.007 | -0.003 |
| Net Change in Cash | 2.7 | -7.778 | -14.957 | -11.147 | -7.226 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Champion River Ventures, Ltd. | Corporation | 10.5833 | 7940937 | 1440000 | 2022-09-30 | |
| Pioneer Step Holdings, Ltd. | Corporation | 9.2197 | 6917783 | 960000 | 2022-09-30 | |
| Nestle Health Science US Holdings, Inc. | Corporation | 5.0869 | 3816794 | 3816794 | 2022-10-17 | |
| Fried (Robert N) | Individual Investor | 4.905 | 3680355 | 168348 | 2023-04-18 | |
| Winsave Resources, Ltd. | Corporation | 4.1161 | 3088433 | 0 | 2021-12-31 | |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.0564 | 3043642 | -84376 | 2023-06-30 | LOW |
| Tieton Capital Management, LLC | Investment Advisor | 3.4254 | 2570148 | 21438 | 2023-06-30 | LOW |
| Black Sheep, FLP | Corporation | 2.7655 | 2075052 | 0 | 2023-04-18 | |
| ICONIQ Capital, LLC | Investment Advisor | 1.7277 | 1296354 | 0 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.2027 | 902444 | 11299 | 2023-06-30 | LOW |
| Farr (Kevin M) | Individual Investor | 1.2001 | 900463 | 185308 | 2023-04-18 | LOW |
| Jaksch (Frank Louis Jr) | Individual Investor | 0.8825 | 662145 | 7000 | 2023-06-12 | LOW |
| Skyinvest Associates Ltd | Corporation | 0.7302 | 547858 | 146965 | 2022-09-30 | |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6989 | 524399 | -33036 | 2023-06-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.6138 | 460539 | 33339 | 2023-06-30 | HIGH |
| DVORAK INTERNATIONAL LIMITED | Corporation | 0.5598 | 420000 | 0 | 2022-09-30 | |
| Radiant Treasure, Ltd. | Corporation | 0.5056 | 379345 | 0 | 2021-12-31 | |
| Gabelli Funds, LLC | Investment Advisor/Hedge Fund | 0.4936 | 370350 | 37000 | 2023-06-30 | LOW |
| GMT Capital Corp. | Hedge Fund | 0.3957 | 296905 | 0 | 2023-06-30 | LOW |
| Millennium Management LLC | Hedge Fund | 0.3746 | 281073 | -231839 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Chromadex Corp Company profile
About Chromadex Corp
ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chromadex Corp revenues increased 14% to $67.4M. Net loss increased 36% to $27.1M. Revenues reflect Consumer Products Segments increase of 20% to $56.7M, Analytical Reference Standards and Service segment increase of 12% to $3.3M. Higher net loss reflects Corporate and other segment loss increase of 19% to $36.4M, Ingredients Segments income decrease of 27% to $3.7M.
Equity composition
Common Stock $.001 Par, 08/11, 150M auth., 60,875,325 issd. Insiders & Strategic holders own 45.88%. 04/16, 1-for-3 recerse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
10900 Wilshire Blvd
Suite 600
LOS ANGELES
CALIFORNIA 90024
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com